arvinas_logoART_lg.jpg
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
08 nov. 2022 07h00 HE | Arvinas Inc.
– On track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer – – Enrolling multiple clinical trials and initiating enrollment...
arvinas_logoART_lg.jpg
Arvinas to Present at Upcoming Conferences
01 nov. 2022 16h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
27 oct. 2022 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation (TPD),...
arvinas_logoART_lg.jpg
Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs
03 oct. 2022 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Gives Back to Local Greater New Haven Community
30 sept. 2022 09h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas to Present at Bank of America Securities Precision Oncology Conference
26 sept. 2022 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas to Present at Upcoming Investor Conferences
31 août 2022 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Announces Changes to its Board of Directors
18 août 2022 16h01 HE | Arvinas Inc.
NEW HAVEN, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations
15 août 2022 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) --  Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Appoints John Northcott as Chief Commercial Officer
01 août 2022 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...